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Abstract
Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug
resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication
often requires surgical removal of infected devices. Here we implicate the molecular chaperone Hsp90 as a key regulator of
biofilm dispersion and drug resistance. We previously established that in the leading human fungal pathogen, Candida
albicans, Hsp90 enables the emergence and maintenance of drug resistance in planktonic conditions by stabilizing the
protein phosphatase calcineurin and MAPK Mkc1. Hsp90 also regulates temperature-dependent C. albicans morphogenesis
through repression of cAMP-PKA signalling. Here we demonstrate that genetic depletion of Hsp90 reduced C. albicans
biofilm growth and maturation in vitro and impaired dispersal of biofilm cells. Further, compromising Hsp90 function in
vitro abrogated resistance of C. albicans biofilms to the most widely deployed class of antifungal drugs, the azoles.
Depletion of Hsp90 led to reduction of calcineurin and Mkc1 in planktonic but not biofilm conditions, suggesting that
Hsp90 regulates drug resistance through different mechanisms in these distinct cellular states. Reduction of Hsp90 levels led
to a marked decrease in matrix glucan levels, providing a compelling mechanism through which Hsp90 might regulate
biofilm azole resistance. Impairment of Hsp90 function genetically or pharmacologically transformed fluconazole from
ineffectual to highly effective in eradicating biofilms in a rat venous catheter infection model. Finally, inhibition of Hsp90
reduced resistance of biofilms of the most lethal mould, Aspergillus fumigatus, to the newest class of antifungals to reach the
clinic, the echinocandins. Thus, we establish a novel mechanism regulating biofilm drug resistance and dispersion and that
targeting Hsp90 provides a much-needed strategy for improving clinical outcome in the treatment of biofilm infections.
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Introduction
In recent decades, fungal pathogens have emerged as a
predominant cause of human disease, especially in immunocom-
promised individuals. The number of acquired fungal bloodstream
infections has increased by ,207% in this timeframe [1,2,3].
Although diverse species are capable of causing infection, a few
prevail as the most prevalent cause of disease. Candida and
Aspergillus species together account for ,70% of all invasive fungal
infections, with Candida albicans and Aspergillus fumigatus prevailing
as the leading causal agents of opportunistic mycoses [2]. Candida
species are the fourth leading cause of hospital acquired
bloodstream infections in the United States with mortality rates
estimated at 40% [4,5]. The profound economic consequences of
Candida infections can be demonstrated by the ,$1.7 billion spent
annually on treating candidemia in the United States alone [6].
Further, A. fumigatus is the most common etiological agent of
invasive aspergillosis, with a 40–90% mortality rate [7]. In patients
with pulmonary disorders such as asthma or cystic fibrosis, A.
fumigatus infection can cause allergic bronchopulmonary aspergil-
losis leading to severe complications. For these fungal species,
there are numerous factors that contribute to the pathogenicity
and recalcitrance of resulting infections to antifungal treatment,
including the ability to evolve and maintain resistance to
conventional antifungal therapy [1].
Due to the limited number of drug targets available to exploit in
fungal pathogens that are absent or sufficiently divergent in the
human host, the vast majority of antifungal drugs in clinical use
target ergosterol or its biosynthesis. The azoles are the most widely
used class of antifungal in the clinic and function by inhibiting the
ergosterol biosynthetic enzyme Erg11, causing a block in the
production of ergosterol and the accumulation of the toxic
byproduct 14-a-methyl-3,6-diol, culminating in a severe mem-
brane stress [8,9]. The azoles are generally fungistatic against
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yeasts, including Candida species, and fungicidal against moulds,
such as Aspergillus species. The fungistatic nature of the azoles
towards C. albicans culminates in strong directional selection on the
surviving population to evolve drug resistance [10,11]. In fact,
high levels of azole resistance in C. albicans clinical isolates often
accumulate through multiple mechanisms including: upregulation
of drug efflux pumps, overexpression or alteration of Erg11, or
modification of stress response pathways that are crucial for
resistance [1,10,11,12,13]. The echinocandins are the only new
class of antifungal to reach the clinic in decades. They act as non-
competitive inhibitors of b-1,3 glucan synthase, an enzyme
involved in fungal cell wall synthesis [9], resulting in the loss of
cell wall integrity and a severe cell wall stress. The impact of the
echinocandins is generally opposite to that of the azoles, in that
they are fungicidal against yeasts and fungistatic against moulds.
Resistance of C. albicans clinical isolates to the echinocandins has
been reported and is often associated with mutations in the drug
target [13,14,15].
An additional key factor responsible for the virulence and drug
resistance of C. albicans and A. fumigatus is their tendency to form
biofilms on medical devices that are highly resistant to antifungal
treatment [16,17,18,19,20]. The use of such medical devices —
such as venous catheters, urinary catheters and artificial joints —
has dramatically risen to more than 10 million recipients per year
[21,22]. This poses a severe clinical problem as C. albicans is the
third leading cause of intravascular catheter-related infections, and
has the overall highest crude mortality rate of ,30% for device-
associated infections [17,22,23]. Further, A. fumigatus infections
have been reported on medical implant devices as well as on
bronchial epithelial cells [17,24]. The inherent drug resistance of
biofilms often necessitates surgical removal of the infected medical
devices in order to eradicate the fungal infection.
Extensive research has focused on mechanisms of drug
resistance in C. albicans biofilms, and it is apparent that cells in a
fungal biofilm represent an epigenetic modification of the cellular
state compared to their planktonic counterparts, with changes in
cellular morphology, cell-to-cell communication, and gene expres-
sion, as well as with the production of an extra-cellular matrix
[16,18,20]. Multiple factors contribute to the elevated drug
resistance of C. albicans biofilms. These factors include increased
cell density [25], increased expression of drug efflux pumps
[26,27], decreased ergosterol content [27], elevated b-1,3 glucan
levels in the cell wall and biofilm matrix [28,29], as well as
signalling mediated by protein kinase C (PKC) [30] and the
protein phosphatase calcineurin [31].
The molecular chaperone Hsp90 regulates complex cellular
circuitry in eukaryotes by stabilizing regulators of cellular
signalling [32,33]. As a consequence, inhibiting Hsp90 disrupts a
plethora of cellular processes and has broad therapeutic potential
against diverse eukaryotic pathogens including the protozoan
parasites Plasmodium falciparum and Trypanosoma evansi as well as
numerous fungal species [34,35,36]. In the planktonic state, Hsp90
potentiates the emergence and maintenance of resistance to azoles
and echinocandins in C. albicans at least in part via calcineurin
[37]; Hsp90 physically interacts with the catalytic subunit of
calcineurin, keeping it stable and poised for activation [38].
Recently, Hsp90 was also shown to enable azole and echinocandin
resistance in C. albicans via the PKC cell wall integrity pathway
[39]. Hsp90 depletion results in the destabilization of the terminal
mitogen-activated protein kinase (MAPK) Mkc1, providing the
second Hsp90 client protein implicated in drug resistance [39].
Compromising C. albicans Hsp90 function renders drug-resistant
isolates susceptible in vitro and improves the therapeutic efficacy
of antifungals in a Galleria mellonella model of C. albicans
pathogenesis and a murine model of disseminated candidiasis
[34]. Compromising A. fumigatus Hsp90 also enhances the efficacy
of echinocandins both in vitro and in the G. mellonella model of
infection [34]. Notably, Hsp90 regulates not only drug resistance
in C. albicans but also the morphogenetic transition between yeast
and filamentous growth, a trait important for virulence [40].
Compromising Hsp90 function induces filamentation by relieving
Hsp90-mediated repression of cAMP-protein kinase A (PKA)
signalling [41]. The ability to transition between morphological
states is also critical for biofilm formation and development [42].
Given that Hsp90 governs fungal morphogenesis and drug
resistance in planktonic conditions, we sought to investigate if this
molecular chaperone also regulates the development and drug
resistance of biofilms. We discovered that genetically compromis-
ing Hsp90 function reduced but did not block biofilm maturation
in vitro and had minimal impact on the ability of C. albicans to
form robust biofilms in an in vivo rat catheter model,. Genetic
depletion of C. albicans Hsp90 reduced biofilm dispersal, with the
few dispersed cells being largely inviable. Moreover, compromis-
ing C. albicans Hsp90 function genetically or pharmacologically
transformed the azole fluconazole from ineffectual to highly
efficacious in eradicating biofilms both in vitro and in a rat
catheter model of infection. In stark contrast to planktonic
conditions, reduction of C. albicans Hsp90 levels genetically in
biofilm conditions did not lead to depletion of the client proteins
calcineurin or Mkc1, suggesting that Hsp90 regulates drug
resistance through distinct mechanisms in these different cellular
states. Genetic depletion of Hsp90 reduced glucan levels in the
biofilm matrix, providing a compelling mechanism by which
Hsp90 might regulate biofilm drug resistance. Finally, in the most
lethal mould, A. fumigatus, compromising Hsp90 function enhanced
the efficacy of azoles and echinocandins in an in vitro model. Our
results implicate Hsp90 as a novel regulator of biofilm dispersion
and drug resistance, and provide strong support for the utility of
Hsp90 inhibitors as a therapeutic strategy for biofilm infections
caused by diverse fungal species.
Author Summary
Candida albicans and Aspergillus fumigatus are the most
common causative agents of fungal infections worldwide.
Both species can form biofilms on host tissues and
indwelling medical devices that are highly resistant to
antifungal treatment. Here we implicate the molecular
chaperone Hsp90 as a key regulator of biofilm dispersion
and drug resistance. Compromising Hsp90 function
reduced biofilm formation of C. albicans in vitro and
impaired dispersal of biofilm cells, potentially blocking
their capacity to serve as reservoirs for infection. Further,
compromise of Hsp90 function abrogated resistance of C.
albicans biofilms to the most widely deployed class of
antifungal, the azoles, both in vitro and in a mammalian
model of catheter-associated candidiasis. Key drug resis-
tance regulators were depleted upon reduction of Hsp90
levels in planktonic but not biofilm conditions, suggesting
that Hsp90 regulates drug resistance through different
mechanisms in these distinct cellular states. Reduction of
Hsp90 markedly reduced levels of matrix glucan, a
carbohydrate important for C. albicans biofilm drug
resistance. Inhibition of Hsp90 also reduced resistance of
A. fumigatus biofilms to the newest class of antifungal, the
echinocandins. Thus, targeting Hsp90 provides a promis-
ing strategy for the treatment of biofilm infections caused
by diverse fungal species.
Regulation of Fungal Biofilms by Hsp90
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Results
Hsp90 is not required for C. albicans biofilm formation in
vitro or in vivo
Due to the key roles of Hsp90 in both morphogenesis and drug
resistance under planktonic conditions [37,41], we hypothesized
that Hsp90 might also regulate C. albicans biofilm formation and
drug resistance. First, we tested whether compromising Hsp90
function affected biofilm growth. To do this, C. albicans biofilms were
cultured for 24 hours in static 96 well microtiter plates, washed to
remove non-adherent cells, grown for an additional 24 hours with
various concentrations of the Hsp90 inhibitor geldanamycin, and
growth was quantified by metabolic activity using an XTT
reduction assay [43]. The geldanamycin was added at 24 hours
rather than at the initial time point as is the standard for biofilm
drug studies since the initial cells are planktonic and much more
susceptible to drugs than their biofilm counterparts [31,43];
consistent with this, initial attempts to include geldanamycin during
inoculation led to a toxicity profile identical to that of planktonic
cells (data not shown). When geldanamycin was added at 24 hours,
no significant differences in metabolic activity were observed at a
variety of concentrations tested up to 100 mg/mL (P.0.05,
ANOVA, Bonferroni’s Multiple Comparison Test, Figure 1A).
Thus, Hsp90 inhibitors do not compromise biofilm development.
To further explore Hsp90’s role in biofilm formation, we
exploited a strain of C. albicans in which Hsp90 levels could be
depleted by tetracycline-mediated transcriptional repression (tetO-
HSP90/hsp90D). Biofilms of the wild type and tetO-HSP90/hsp90D
strain were cultured in static 96 well microtiter plates with or
without 20 mg/mL of the tetracycline analog doxycycline from the
time of inoculation. Doxycycline was included at this early point
given the time required for transcriptional repression to manifest in
depletion of Hsp90, and enabled by the absence of toxicity in
planktonic cells. Doxycycline-mediated transcriptional repression of
Hsp90 decreased biofilm development, but did not block formation
of a mature biofilm (Figure 1B, P,0.01). We observed comparable
results when biofilms were cultured on silicon elastomer squares,
and when biofilm growth was monitored by XTT reduction or by
dry weight (Figure S1A and B). To determine if depletion of Hsp90
prior to inoculation had a more profound effect on biofilm
formation, we performed a comparable assay but in the presence
or absence of doxycycline in the overnight culture. Depletion of
Hsp90 prior to inoculation did not further reduce biofilm formation
but rather led to a biofilm indistinguishable from the no doxycycline
control (Figure S1C). Although Hsp90 is essential, this dose of
doxycycline causes reduced growth rate of the tetO-HSP90/hsp90D
strain in planktonic cultures but has little effect on stationary phase
cell density [41]. Western blot analysis validated that Hsp90 levels
were dramatically reduced in biofilms formed by the tetO-HSP90/
hsp90D strain when cultured in the presence of doxycycline
(Figure 1C). We note that when biofilms were formed under
shaking conditions, the tetO-HSP90/hsp90D strain had reduced
biofilm growth, which was exacerbated in the presence of
doxycycline (Figure S1D). Thus, while Hsp90’s impact on biofilm
development can vary, under most conditions tested compromising
Hsp90 function does not block biofilm formation in vitro.
Figure 1. Compromise of Hsp90 function does not block C.
albicans biofilm development in vitro. (A) Biofilms were grown in
96-well microtiter plates in RPMI at 37uC. After 24 hours wells were
washed with PBS to remove non-adherent cells and fresh RPMI medium
was added containing various concentrations of the Hsp90 inhibitor
geldanamycin (GdA). Biofilms were grown for an additional 24 hours at
37uC. Metabolic activity was measured using an XTT reduction assay
and quantified by measuring absorbance at 490 nm. Error bars
represent standard deviations of five technical replicates. Biofilm
growth in the presence of GdA was not significantly different from
the untreated control (P.0.05, ANOVA, Bonferroni’s Multiple Compar-
ison Test). (B) Strains of C. albicans were grown in 96-well microtiter
plates in RPMI at 37uC for 24 hours with or without 20 mg/mL
doxycycline (DOX). Metabolic activity was measured as in Figure 1A.
Doxycycline-mediated transcriptional repression of HSP90 in the tetO-
HSP90/hsp90D strain yielded a small reduction in biofilm growth
(P,0.01). Asterisk indicates P,0.01 compared to all other conditions.
Error bars represent standard deviations from five technical replicates.
(C) Hsp90 levels are dramatically reduced in a C. albicans biofilm upon
treatment of the tetO-HSP90/hsp90D strain with 20 mg/mL doyxcycline
in RPMI at 37uC. Total protein was resolved by SDS-PAGE and blots were
hybridized with a-Hsp90 and a-tubulin as a loading control.
doi:10.1371/journal.ppat.1002257.g001
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In order to address the role of Hsp90 in biofilm growth in vivo,
biofilm formation was examined using a rat venous catheter model
of biofilm-associated candidiasis that mimics central venous
catheters in patients [44]. Infection of implanted catheters with
C. albicans was performed by intraluminal instillation, catheters
were flushed after 6 hours, and biofilm formation was monitored
with or without 20 mg/mL doxycycline after 24 hours. The tetO-
HSP90/hsp90D strain was capable of establishing a biofilm in the
rat venous catheter, as visualized by scanning electron microscopy
(Figure 2). Further, transcriptional repression of HSP90 with
doxycycline did not block the formation of a robust biofilm
(Figure 2). These results demonstrate that compromising Hsp90
function does not impair the ability of C. albicans to form mature
biofilms in vivo.
Compromising Hsp90 function produces biofilms with
altered morphologies
As mentioned above, Hsp90 is a key regulator of the yeast to
filament transition in C. albicans [41], a process implicated in
virulence and biofilm formation [42]. Therefore, we examined
the architecture of geldanamycin treated biofilms cultured on
silicon elastomer squares to enable imaging by confocal
microscopy. Biofilms treated with geldanamycin had decreased
thickness of the bottom yeast layer (30 mm and 45 mm versus
90 mm and 100 mm in the untreated control, P= 0.0237, t-test)
without substantial change in the thickness of the upper layer of
filaments (Figure 3). That a greater proportion of the biofilm
thickness was occupied by filaments compared to yeast suggests
that Hsp90 inhibition might lead to enhanced filamentation in
biofilms. Moreover, biofilms treated with geldanamycin showed
more polarized filaments extending away from the biofilm basal
surface compared to the interconnected meshwork of filaments in
an untreated control (Figure 3). That biofilms formed upon
Hsp90 inhibition had a greater proportion of their total thickness
occupied by filaments compared to yeast is consistent with
Hsp90’s repressive effect on filamentation in planktonic condi-
tions.
Figure 2. Genetic depletion of Hsp90 does not block C. albicans biofilm formation in vivo. The tetO-HSP90/hsp90D strain was inoculated in
rat venous catheters in the presence or absence of 20 mg/mL doxycycline (DOX). Biofilms were examined by scanning electron microscopy imaging at
24 hours. The top row represents 50 X magnification while the bottom row represents 1,000 X magnification. Biofilm thickness and structure were
similar in the presence or absence of doxycycline.
doi:10.1371/journal.ppat.1002257.g002
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Hsp90 function is important for dispersal of C. albicans
biofilms
Based on our finding that C. albicans biofilms display altered
morphologies upon Hsp90 inhibition, we sought to evaluate the
effect of Hsp90 function on biofilm dispersion given that
morphogenesis plays a critical role in this process [45,46]. We
monitored dispersion of yeast cells using the only well validated
model which involves culturing biofilms on silicon elastomer under
conditions of flow [47,48]. When biofilms were cultured in the
absence of doxycycline with the tetO-HSP90/hsp90D strain, the
number of dispersed cells after 1 hour was 90,000 cells/mL and
remained fairly constant over a 24 hour time period (Figure 4A).
In contrast, in the presence of 20 mg/mL doxycycline the number
of dispersed cells was dramatically reduced to approximately
17,000 cells/mL throughout the 24 hours (P=0.0022, t-test,
Figure 4A). We confirmed that the effects of doxycycline were
Figure 3. Pharmacological inhibition of Hsp90 alters C. albicans biofilms architecture. C. albicans cells were grown on silicon elastomer
squares in RPMI at 37uC for 24 hours. C. albicans wild-type biofilms were left untreated (A), or treated with 10 mg/mL geldanamycin (GdA) for
48 hours (B). Biofilms were stained with concanavalin A conjugate for confocal scanning laser microscopy visualization, and image reconstructions
were created to provide side views (top panel). Representative images are shown. Confocal scanning laser microscopy depth views were artificially
coloured (middle panel) with blue representing within 10 mm from the silicon, orange representing approximately 300 mm from the silicon, and red
representing over 400 mm from the silicon. Scanning electron microscopy images are shown in bottom panel. Biofilms treated with GdA show a
thinner lower layer of yeast than the untreated control.
doi:10.1371/journal.ppat.1002257.g003
Regulation of Fungal Biofilms by Hsp90
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specifically due to transcriptional repression of HSP90, as
doxycycline had no impact on biofilm dispersal of the wild-type
strain lacking the tetO promoter (Figure S2A). Intriguingly, the cells
that were dispersed upon reduction of Hsp90 levels had major
viability defects compared to their untreated counterparts
(P=0.007, t-test) with only 55% viable at 1 hour, 5% viable at
12 hours, and less than 1% viable at 24 hours (Figure 4B). The
dramatic reduction in viability was specific to the dispersed cell
population with doxycycline-mediated transcriptional repression
of HSP90, as the viability of dispersed cells in the untreated control
remained close to 50% even at 24 hours (Figure 4B). Viability was
unaffected when a wild-type strain lacking the tetO promoter was
treated with doxycycline, confirming that the effects observed were
due to transcriptional repression of HSP90 (Figure S2B). The
reduced viability upon reduction of Hsp90 levels was specific to
the dispersed cell population within the biofilm, as there was only a
minor defect in overall metabolic activity of the tetO-HSP90/
hsp90D biofilms in the presence of doxycycline (Figure 1B).
Further, under planktonic conditions viability remained.85%
when the tetO-HSP90/hsp90D strain was grown in the presence of
doxycycline for 24 hours. Taken together, Hsp90 plays a critical
role in the dispersal step of the biofilm life cycle and is crucial for
survival of dispersed cells.
Hsp90 enables the resistance of C. albicans biofilms to
fluconazole in vitro
Genetic or pharmacological compromise of Hsp90 function
renders C. albicans susceptible to azoles and echinocandins under
planktonic conditions [37,38,49]. Since compromising Hsp90
function pharmacologically did not impair biofilm maturation, we
investigated whether inhibition of Hsp90 would alter biofilm drug
resistance using the standard 96 well microtiter plate static assay
that enables testing many drug concentrations. We focused on the
azoles, since biofilms are notoriously resistant to this class of drugs,
compromising their therapeutic utility [19]. As a positive control, a
wild-type C. albicans biofilm was subjected to a gradient of
concentrations of the calcineurin inhibitor FK506 in addition to a
gradient of fluconazole, a drug combination with established
synergistic activity against C. albicans biofilms [31]. We confirmed
Figure 4. Depletion of Hsp90 reduces biofilm dispersion and viability of the dispersed cell population. C. albicans biofilms from the
tetO-HSP90/hsp90D strain were cultured in the presence or absence of 20 mg/mL doxycycline (DOX). (A) The number of dispersed cells released from
biofilms was monitored over a 24 hour period. (B) The viability of dispersed cells was determined by plating on YPD agar.
doi:10.1371/journal.ppat.1002257.g004
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Figure 5. Inhibition of Hsp90 function dramatically enhances the efficacy of fluconazole against C. albicans biofilms in vitro. (A)
Strains of C. albicans were grown in 96-well microtiter plates in RPMI at 37uC. After 24 hours cells were washed with PBS to remove non-adherent cells
and fresh medium was added with varying concentrations of the azole fluconazole (FL) and either the calcineurin inhibitor FK506 or the Hsp90
inhibitor geldanamycin (GdA) in a checkerboard format. Metabolic activity was measured as in Figure 1A. The FIC index was calculated as indicated in
Table 1. Bright green represents growth above the MIC50, dull green represents growth at the MIC50, and black represents growth below the MIC50.
Data was quantitatively displayed with colour using the program Java TreeView 1.1.3 (http://jtreeview.sourceforge.net). Inhibiting calcineurin or
Hsp90 function has synergistic activity with fluconazole. (B) Strains of C. albicans were grown in 96-well microtiter plates in RPMI at 37uC. When
indicated, 20 mg/mL doxycycline (DOX) was added to the medium. After 24 hours cells were washed with PBS to remove non-adherent cells and fresh
medium was added with varying concentrations of fluconazole. Metabolic activity was measured as in Figure 1A. Genetic depletion of Hsp90 reduces
the MIC50 of fluconazole to a greater extent than deletion of its client proteins calcineurin or Mkc1.
doi:10.1371/journal.ppat.1002257.g005
Table 1. Inhibition of calcineurin or Hsp90 has synergistic activity with fluconazole against wild-type C. albicans biofilms.
Inhibitor, concentration range (mg/mL) Fluconazole concentration range (mg/mL) FIC indexa
FK506, 4.6875–75 62.5–1000 0.1093
GdA, 6.25–100 62.5–1000 0.125
GdA, 3.125–100 125–1000 0.156
aFIC index (MIC50 of drug A in combination)/(MIC50 of drug A alone) + (MIC50 of drug B in combination)/(MIC50 of drug B alone). A FIC of ,0.5 is indicative of synergism.
doi:10.1371/journal.ppat.1002257.t001
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synergistic activity of FK506 with fluconazole by measuring
metabolic activity using the XTT reduction assay (Figure 5A).
Biofilms were extremely susceptible to the combination of
inhibitors with a calculated FIC index of 0.1093, indicating potent
synergy (Table 1). To determine if Hsp90 enables biofilm azole
resistance, we used an equivalent experiment but with a gradient
of concentrations of the Hsp90 inhibitor geldanamycin and a
gradient of fluconazole. Geldanamycin exhibited potent synergy
with fluconazole, dramatically reducing azole resistance at only
3.125 mg/mL geldanamycin. Maximal effects were observed with
12.5 mg/mL geldanamycin, which reduced the MIC50 of flucon-
azole from .1000 mg/mL to 31.25 mg/mL (Figure 5A). Further,
FIC indexes as low as 0.125 to 0.156 were calculated for the
combination of fluconazole and geldanamycin confirming that
inhibition of Hsp90 has a potent synergistic effect with azoles
against C. albicans biofilms (Table 1).
Next, we utilized the tetO-HSP90/hsp90D strain in order to
validate that the synergistic activity of geldanamycin with
fluconazole against C. albicans biofilms was indeed due to Hsp90
inhibition. Biofilms of a wild-type strain of C. albicans had a
fluconazole MIC50 of over 512 mg/mL (Figure 5B). Deletion of
one allele of HSP90 or replacing the promoter of the sole
remaining HSP90 allele with the tetracycline-repressible pro-
moter had no impact on fluconazole resistance (Figure 5B).
However, upon depletion of Hsp90 by doxycycline-mediated
transcriptional repression in the tetO-HSP90/hsp90D strain, the
fluconazole MIC50 was dramatically reduced to only 8 mg/mL,
a .60-fold increase in fluconazole sensitivity (Figure 5B).
Hence, both pharmacological and genetic evidence confirms
that Hsp90 function is critical for azole resistance of C. albicans
biofilms.
The role of downstream effectors of Hsp90 in azole
resistance of C. albicans biofilms
To further dissect the mechanism by which Hsp90 regulates
azole resistance of C. albicans biofilms, we repeated the drug
susceptibility assay with strains lacking specific Hsp90 client
proteins. Under planktonic conditions both calcineurin and Mkc1
are important Hsp90 client proteins that regulate the mainte-
nance of azole resistance [37,38,39]. Moreover, these client
proteins have previously been shown to be important for azole
resistance of C. albicans biofilms [30,31]. We found that biofilms
formed by strains lacking the catalytic subunit of calcineurin
(cna1D/cna1D) or the terminal MAPK of the PKC cell wall
integrity signalling pathway (mkc1D/mkc1D) had fluconazole
MIC50 values of 32 mg/mL and 128 mg/mL, respectively; their
fluconazole resistance levels were intermediate between the
robust resistance of the wild-type parental strain and the
sensitivity observed upon impairment of Hsp90 function
(Figure 5B). The finding that compromise of calcineurin function
does not confer as severe a reduction in biofilm fluconazole
resistance as compromise of Hsp90 function is intriguing in light
of the fact that under all planktonic conditions tested, inhibition
of calcineurin phenocopies inhibition of Hsp90 in terms of azole
resistance [37,38,49]. These results suggest that calcineurin and
Mkc1 may be able to partially compensate for the loss of the
other client during times of azole-induced stress in a biofilm
environment. Alternatively, these findings could be explained by
the existence of a novel downstream effector of Hsp90 important
for azole resistance of C. albicans biofilms.
To further investigate the mechanisms by which Hsp90
regulates azole resistance in biofilm conditions, we examined
protein levels of the client proteins calcineurin and Mkc1 upon
Hsp90 depletion. Strains were cultured in RPMI medium for
both planktonic and biofilm growth. Biofilms were cultured on
plastic under static conditions, as with our drug studies. We
previously established that under planktonic conditions genetic
reduction of Hsp90 levels leads to depletion of the catalytic
subunit of calcineurin (Cna1) and Mkc1 [38,39]. Here, the tetO-
HSP90/hsp90D strain was grown in either planktonic or biofilm
conditions in the presence or absence of 20 mg/mL doxycycline
for 48 hours. Under both conditions, Hsp90 levels were
dramatically reduced in the presence of doxycycline (Figure 6).
To monitor calcineurin levels, we used a C-terminal 6xHis-FLAG
epitope tag on Cna1 in the tetO-HSP90/hsp90D strain. In the
tagged strains, Cna1 levels were comparable under planktonic
and biofilm conditions in the absence of doxycycline (Figure 6A).
Doxycycline-mediated reduction of Hsp90 levels led to an ,90%
reduction in Cna1 in planktonic conditions, however, Cna1 levels
remained stable in biofilm conditions (Figure 6A). All strains had
comparable amounts of protein loaded, as confirmed with a
tubulin loading control. To monitor total Mkc1 levels, we used a
C-terminal 6xHis-FLAG epitope tag on Mkc1 in the tetO-HSP90/
hsp90D strain. Mkc1 levels were comparable in the tagged strains
under planktonic and biofilm conditions in the absence of
doxycycline (Figure 6B). As with Cna1, doxycycline-mediated
reduction of Hsp90 levels led to ,80% reduction in Mkc1 levels
in planktonic conditions, however, Mkc1 levels remained stable in
biofilm conditions (Figure 6B). We next addressed whether
depletion of Hsp90 affected levels of activated, dually phosphor-
ylated Mkc1. Mkc1 was activated in all strains in the absence of
doxycycline. As with total Mkc1 levels, doxycycline-mediated
reduction of Hsp90 led to a reduction in levels of activated Mkc1
in planktonic conditions, however, Mkc1 remained activated in
biofilm conditions. Taken together, these results suggest that
Hsp90 may play different roles in client protein regulation in
these distinct cellular states, and also that these client proteins
may have other means of maintaining stability in a biofilm
environment.
Hsp90 regulates matrix glucan levels in C. albicans
biofilms
Given our findings that Hsp90 client proteins remain stable in a
biofilm, irrespective of Hsp90 levels, and that deletion of these
client proteins does not phenocopy Hsp90 depletion in terms of
biofilm azole resistance, we hypothesized that Hsp90 also regulates
biofilm drug resistance through a mechanism independent of
calcineurin and Mkc1 signalling. Recent studies established that
glucan present in the biofilm matrix is critical for azole resistance
due its capacity to sequester fluconazole, preventing it from
reaching its intracellular target [29]. Consequently, we investigat-
ed whether Hsp90 affects glucan levels in the biofilm matrix.
Biofilms were cultured on plastic in static conditions in the
presence or absence of 20 mg/mL doxycycline for 48 hours,
matrix material was harvested from biofilms with equivalent
metabolic activity, and b-1,3 glucan levels were quantified. In the
tetO-HSP90/hsp90D strain, the level of glucan in the biofilm matrix
was ,6,000 pg/mL in the absence of doxycycline (Figure 7).
Transcriptional repression of HSP90 with 20 mg/mL doxycycline
led to reduced glucan levels of only ,3,700 pg/mL (P,0.01,
ANOVA, Bonferroni’s Multiple Comparison Test, Figure 7).
Doxycycline had no impact on matrix glucan levels of a wild-type
strain lacking the tetO promoter, confirming that Hsp90 depletion
leads to reduced glucan levels (Figure 7). The ,40% reduction in
matrix glucan upon Hsp90 depletion is likely to have made a
major contribution to azole susceptibility, given that reduction of
biofilm matrix glucan levels of ,60% in an FKS1/fks1D mutant
abrogates biofilm drug resistance [29]. These results provide the
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Figure 6. The Hsp90 client proteins Cna1 and Mkc1 exhibit reduced dependence on Hsp90 for stability under biofilm compared to
planktonic conditions. (A) Genetic depletion of Hsp90 does not reduce calcineurin levels in biofilm conditions. The tetO-HSP90/hsp90D strain with
one allele of CNA1 C-terminally 6xHis-FLAG tagged was grown in planktonic or biofilm conditions with or without doxycycline (DOX, 20 mg/mL) for
48 hours. Total protein was resolved by SDS-PAGE and blots were hybridized with a-Hsp90, a-FLAG to monitor calcineurin levels, and a-tubulin as a
loading control (left panel). Cna1 levels from two independent Western blots were quantified using ImageJ software (http://rsb.info.nih.gov/ij/index.
html). The density of bands obtained for Cna1 was normalized relative to the density of bands for the corresponding tubulin loading control. Levels
were subsequently normalized to the untreated control for the planktonic or biofilm state (right panel). (B) Depletion of Hsp90 does not deplete
Mkc1 in biofilm conditions. The tetO-HSP90/hsp90D strain with one allele of MKC1 C-terminally 6xHis-FLAG tagged was grown in planktonic or biofilm
conditions with or without DOX for 48 hours. Total protein was resolved by SDS-PAGE and blots were hybridized with a-Hsp90, a-His6 to monitor
Mkc1 levels, a-phospho-p44/42 to monitor dually phosphorylated Mkc1, and a-tubulin as a loading control (left panel). Mkc1 levels from two
independent Western blots were quantified using ImageJ software. The density of bands for Mkc1 was normalized relative to the density of bands for
the tubulin loading control. Levels were subsequently normalized to the untreated control for the planktonic or biofilm state (right panel).
doi:10.1371/journal.ppat.1002257.g006
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first link of Hsp90 to glucan production in C. albicans and
mechanistic insight as to how Hsp90 regulates biofilm drug
resistance.
Hsp90 is required for C. albicans biofilm azole resistance
in vivo
Due to the robust synergy observed between Hsp90 inhibition
and fluconazole in vitro, we sought to address whether synergy was
also observed in vivo in the rat venous catheter model of C. albicans
biofilm infection using the tetO-HSP90/hsp90D strain. Addition of
fluconazole alone (250 mg/mL) after 24 hours of biofilm growth
did not affect the biofilm formed by the tetO-HSP90/hsp90D strain
(Figure 8A). Doxycycline was delivered during both the biofilm
formation and drug treatment phases, and also had no major effect
on the biofilm formed by the tetO-HSP90/hsp90D strain (Figure 2).
However, the combination of fluconazole and doxycycline
destroyed the biofilm as observed by scanning electron microscopy
(Figure 8A). Thus, Hsp90 is required for the resistance of C.
albicans biofilms to fluconazole in a mammalian host.
In order to further explore the therapeutic potential of targeting
Hsp90 for C. albicans biofilm infections in vivo, we explored the
efficacy of combining fluconazole with an Hsp90 inhibitor
structurally related to geldanamycin and in clinical development as
an anti-cancer agent, 17-(allylamino)-17-demethoxygeldanamycin
(17-AAG). Central venous rat catheters were infected with C. albicans
and biofilm formation proceeded over a 24-hour period. At this
point, fluconazole alone (250 mg/mL), 17-AAG alone (100 mg/mL),
or the drug combination was instilled and allowed to dwell in the
catheter for an additional 24 hours. Serial dilutions of the catheter
fluid were then plated in order to assess viable colony forming units.
We found that the combined drug treatment significantly reduced
fungal burden compared to the individual drug treatments alone
(P,0.001, ANOVA, Bonferroni’s Multiple Comparison Test,
Figure 8B). In fact, catheters from the animals undergoing the
combination therapy were completely sterile (Figure 8B). These
experiments in a mammalian model provide compelling evidence
that clinically relevant Hsp90 inhibitors may prove to be extremely
valuable in combating C. albicans biofilm infections.
Hsp90 is required for drug resistance of A. fumigatus
biofilms
We previously established that Hsp90 inhibitors increase the
efficacy of the echinocandins against A. fumigatus under standard
culture conditions [34], motivating these studies to determine if
Hsp90 inhibitors also affect drug resistance of A. fumigatus biofilms.
After 24 hours of growth, A. fumigatus biofilms were subjected to a
gradient of concentrations of the echinocandins caspofungin or
micafungin, or the azoles voriconazole or fluconazole, in addition
to a gradient of concentrations of the Hsp90 inhibitor geldana-
mycin in 96 well microtiter plates under static conditions.
Metabolic activity was assessed using the XTT reduction assay
after an additional 24 hours. The biofilms were completely
resistant to all the antifungal drugs tested and geldanamycin
individually, though the combination of geldanamycin with many
of the antifungals was effective in reducing biofilm development.
Geldanamycin displayed robust synergy with both caspofungin
(Figure 9A) and micafungin (Figure S3A), with an FIC value of
0.375 for both drugs (Table 2). Geldanamycin also enhanced
voriconazole activity (Figure 9A), with more potent effects
observed when drugs were added to biofilms after only 8 hours
of growth (Figure S3B). Geldanamycin did not enhance the
efficacy of fluconazole under any conditions tested (data not
shown). These patterns of drug synergy observed with A. fumigatus
biofilms are consistent with those patterns observed with Aspergillus
in planktonic conditions [37].
Next, given Hsp90’s role in regulating fungal morphogenesis we
explored the impact of drug treatment on morphology of A.
fumigatus biofilms. Scanning electron microscopy revealed striking
architectural changes of A. fumigatus biofilms upon drug treatment.
The control biofilms appeared robust and healthy, however, upon
Hsp90 inhibition increased hyphal and matrix production was
observed (Figure 9B). Treating biofilms with caspofungin alone
resulted in minimal damage, however, the addition of both
caspofungin and geldanamycin caused numerous burst and broken
hyphae throughout the biofilm (Figure 9B). Finally, voriconazole
treatment resulted in a flat ribbon-like morphology, and the
addition of geldanamycin induced further cell damage (Figure 9B).
Figure 7. Depletion of Hsp90 reduces biofilm matrix glucan. Strains of C. albicans were cultured in 6-well polystyrene dishes for 48 hours with
or without 20 mg/mL doxycycline (DOX). Matrix samples were collected and matrix b-1,3 glucan levels were meausured using a limulus lysate based
assay. Asterisk indicates P,0.01 (ANOVA, Bonferroni’s Multiple Comparison Test) compared to all other conditions.
doi:10.1371/journal.ppat.1002257.g007
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Figure 8. Compromise of Hsp90 function genetically or pharmacologically enhances the efficacy of fluconazole in vivo. (A) The tetO-
HSP90/hsp90D strain was inoculated in rat venous catheters for 24 hours with or without 20 mg/mL doxycycline (DOX) followed by intraluminal azole
treatment for an additional 24 hours. Following drug exposure, catheters were removed for visualization by scanning electron microscopy. The first
column represents treatment with 250 mg/mL fluconazole (FL), followed by treatment with both 20 mg/mL DOX and 250 mg/mL FL. The top row
represents 50 X magnification and the bottom row represents 1,000 X magnification. The combination of FL and DOX abrogates biofilms. (B) Biofilms
were cultured as in A with 250 mg/mL FL, 100 mg/mL 17-AAG, or the combination of drugs. Serial dilutions of the catheter fluid were plated for viable
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Taken together, these results indicate that inhibition of Hsp90
induces changes in morphology of A. fumigatus biofilms, in addition
to enhancing the efficacy of azoles and echinocandins against these
otherwise recalcitrant cellular structures.
Discussion
Our results establish a novel role for Hsp90 in dispersion and
drug resistance of fungal biofilms, with profound therapeutic
potential. Resistance of C. albicans biofilms to many antifungal
drugs including the azoles, often necessitates surgical removal of
the infected catheter or substrate demanding new therapeutic
strategies. Here, we demonstrate that compromising the function
of C. albicans Hsp90 blocks biofilm dispersal, potentially reducing
their ability to serve as reservoirs for persistent infection (Figure 4).
Further, we show that compromising Hsp90 function genetically
or pharmacologically in C. albicans renders biofilms exquisitely
susceptible to azoles, such that fluconazole is transformed from
inefficacious to highly effective in destroying biofilms both in vitro
(Figure 5 and Table 1) and in a mammalian model of infection
(Figure 8). Finally, in A. fumigatus we found that compromising
Hsp90 function dramatically improves the efficacy of antifungals
(Figure 9). Thus, inhibition of Hsp90 enhances the efficacy of
antifungals against biofilms formed by the two leading fungal
pathogens of humans separated by ,1 billion years of evolution,
suggesting that this combinatorial therapeutic strategy could have
a broad spectrum of activity against diverse fungal pathogens.
Hsp90 exerts pleiotropic effects on cellular circuitry in
eukaryotes by stabilizing diverse regulators of cellular signalling
[32,33,50]. Hsp90 regulates the temperature-dependent morpho-
genetic transition from yeast to filamentous growth in C. albicans,
such that compromise of Hsp90 function by elevated temperature
relieves Hsp90-mediated repression of Ras1-PKA signalling and
induces filamentous growth [41]. While compromise of Hsp90
function could have impaired biofilm development by enhancing
filamentous growth, we found negligible impact on biofilm
development in vivo (Figure 2); in vitro, compromise of Hsp90
function did reduce biofilm maturation under static conditions
with more severe effects under shaking conditions (Figures 1 and
S1). Biofilms formed in the presence of Hsp90 inhibitor had a
greater proportion of their total thickness occupied by filaments
compared to yeast (Figure 3), suggesting that Hsp90’s role in
repressing the yeast to filament transition in planktonic cells [41] is
conserved in the biofilm state. Consequently, we investigated the
impact of compromising Hsp90 function on dispersion, a stage of
the biofilm life cycle intimately coupled to morphogenetic
transitions, with the majority of dispersed cells being in the yeast
form [45,46]. We found that compromising Hsp90 function
dramatically reduces the dispersed cell population (Figure 4),
consistent with previous findings with hyperfilamentous C. albicans
mutants [45,46]. Strikingly, the majority of cells that disperse from
biofilms with reduced levels of Hsp90 are inviable (Figure 4),
which likely reflects an enhanced dependence of this cell
population on Hsp90. Given that the dispersed cell population is
thought to be responsible for device-associated candidemia and
the establishment of disseminated infection, inhibition of C. albicans
Hsp90 function in individuals suffering from biofilm infections
may assist in the prevention of the invasive forms of disease. In the
broader sense, it is striking that depletion of Hsp90 blocks the
production of yeast in C. albicans in planktonic conditions [41] as
well as throughout the biofilm lifecycle, creating a constitutively
filamentous program characteristic of the strictly filamentous
lifestyle of the vast majority of fungi.
Hsp90 potentiates the emergence and maintenance of C. albicans
drug resistance through multiple client proteins. A key mediator of
Hsp90-dependent drug resistance is the protein phosphatase
calcineurin [37,38,49]. In planktonic cells, Hsp90 stabilizes the
catalytic subunit of calcineurin, Cna1, thereby enabling calci-
neurin-dependent cellular signalling required for survival of drug-
induced cellular stress [38]. Hsp90 also regulates drug resistance
by stabilizing the MAPK Mkc1, thereby enabling additional stress
responses important for resistance [39]. In planktonic conditions,
inhibition of calcineurin phenocopies inhibition of Hsp90 reducing
drug resistance of diverse mutants, though deletion of MKC1 has a
less severe effect on resistance under specific conditions [37,38,39].
In biofilms, homozygous deletion of either CNA1 or MKC1 causes
an intermediate increase in sensitivity to azoles compared to
reduction of HSP90 levels (Figure 5). Genetic depletion of Hsp90
reduces the fluconazole MIC50 from .512 mg/mL to 8 mg/mL,
whereas deletion of CNA1 reduces resistance to 32 mg/mL and
deletion ofMKC1 reduces resistance only to 128 mg/mL (Figure 5).
Thus, both calcineurin and Mkc1 have reduced impact on azole
resistance of biofilms compared to Hsp90, suggesting differences in
the Hsp90-dependent cellular circuitry between the biofilm and
planktonic cellular states.
Hsp90 regulates circuitry required for fungal drug resistance
largely by stabilizing key regulators of cellular signalling. In
planktonic conditions, reduction of Hsp90 levels leads to depletion
of both Cna1 and Mkc1 [38,39]. In stark contrast, Cna1 and
Mkc1 remain stable in biofilms, despite reduction of Hsp90 levels
(Figure 6). In both planktonic and biofilm conditions, Hsp90 levels
were reduced by doxycycline-mediated transcriptional repression
in the tetO-HSP90-hsp90D strain and levels of Hsp90 were reduced
sufficiently to abrogate drug resistance in both conditions. The
reduced dependence of Cna1 and Mkc1 on Hsp90 in biofilms
suggests that these proteins have altered stability in this cellular
state. These Hsp90 client proteins may assume an alternate
conformation in biofilms that is inherently more stable, or they
may interact with other proteins or chaperones that confer
increased stability and reduced dependence upon Hsp90.
Consistent with the possibility of altered chaperone balance in
biofilm cells, the Hsp70 family member SSB1 is overexpressed six-
fold in biofilms compared to their planktonic counterparts [51].
While it is possible that Hsp90 may still regulate Cna1 and Mkc1
function through a mechanism distinct from protein stability, we
note that Mkc1 is still activated upon Hsp90 depletion in biofilms
(Figure 6). Given Hsp90’s high degree of connectivity in diverse
signalling cascades, it could also affect biofilm drug resistance in a
multitude of other ways, such as by regulating remodeling of the
cell wall and cell membrane [27,28], signalling cascades important
for matrix production [29,52], or the function of contact-
dependent signalling molecules that initiate responses to surfaces
[30]. Future studies will determine on a more global scale the
impact of cellular state on Hsp90 client protein stability, and the
complex circuitry by which Hsp90 regulates biofilm drug
resistance.
Our results suggest that Hsp90 is a novel regulator of matrix
glucan levels. For C. albicans the reduction in matrix glucan levels
upon Hsp90 depletion provides a mechanism by which Hsp90
might govern biofilm azole resistance. C. albicans biofilms possess
fungal colony counts. Results are expressed as the mean colony forming unit (CFU) per catheter. The combination of FL and 17-AAG reduces fungal
burden in the catheter compared to individual drug treatments (Asterisk indicates P,0.001, ANOVA, Bonferroni’s Multiple Comparison Test).
doi:10.1371/journal.ppat.1002257.g008
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Figure 9. Pharmacological inhibition of Hsp90 enhances the efficacy of echinocandins and azoles against A. fumigatus biofilms and
affects biofilm morphology. (A) A. fumigatus was grown in 96-well dishes in RPMI at 37uC. After 24 hours cells were washed with PBS to remove
non-adherent cells and fresh medium was added with varying concentrations of the echinocandin caspofungin (CF), the azole voriconazole (VL), and
the Hsp90 inhibitor geldanamycin (GdA) in a checkerboard format. Drug treatment was left on for 24 hours. Metabolic activity was measured as in
Figure 1A. The FIC index was calculated as indicated in Table 2. Bright green represents growth above the MIC50, dull green represents growth at the
MIC50, and black represents growth below the MIC50. (B) A. fumigatus cells were left untreated, or treated with 32 mg/mL CF or 256 mg/mL VL in the
absence and presence of 50 mg/mL GdA for 24 hours. Following drug exposure, biofilms were fixed and imaged by scanning electron microscopy.
Biofilms treated with antifungal show increased cellular damage in the presence of GdA. The white arrows indicate burst and broken hyphae in the
biofilms treated with CF and GdA.
doi:10.1371/journal.ppat.1002257.g009
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elevated cell wall b-1,3 glucan content compared to their
planktonic counterparts [28], and matrix glucan sequesters
fluconazole, preventing it from reaching its intracellular target
[28,29]. The ,40% reduction in matrix glucan we observed upon
Hsp90 depletion (Figure 7) likely contributes to reduced azole
resistance, given that a reduction of matrix glucan levels of ,60%
in an FKS1/fks1D mutant abrogates biofilm drug resistance [29].
Hsp90 could regulate glucan levels by directly or indirectly
affecting b-1,3 glucan synthase, Fks1, a protein important for the
production of matrix glucan and for antifungal resistance [28,29].
Alternatively, Hsp90 could regulate matrix production by directly
or indirectly affecting Zap1, or its downstream targets Gca1 and
Gca2, which play an important role in matrix production, likely
through the hydrolytic release of b-glucan fragments from the
environment [52]. We note that in A. fumigatus, inhibition of Hsp90
appears to increase matrix production (Figure 9), though glucan
levels remain unknown. Future studies will dissect the molecular
mechanisms by which Hsp90 regulates biofilm matrix production
and if there is divergent circuitry between these fungal pathogens.
This work establishes that targeting Hsp90 may provide a
powerful therapeutic strategy for biofilm infections caused by the
leading fungal pathogens of humans. Compromising Hsp90
function genetically or pharmacologically reduces azole resistance
of C. albicans biofilms both in vitro and in the rat venous catheter
model of infection (Figures 5 and 8). Importantly, inhibition of
Hsp90 with 17-AAG, an Hsp90 inhibitor that has advanced in
clinical trials for the treatment of cancer [53,54] and is synergistic
with antifungals in planktonic conditions [34], transforms
fluconazole from ineffective to highly efficacious in a mammalian
model of biofilm infection (Figure 8). There may in fact be a
multitude of benefits of inhibiting Hsp90 in the context of C.
albicans biofilm infections given a recent report that treatment of in
vitro C. albicans biofilms with voriconazole induces resistance to
micafungin in an Hsp90-dependent manner [55]. The therapeutic
potential of Hsp90 inhibitors against fungal biofilms extends
beyond C. albicans to the most lethal mould, A. fumigatus.
Pharmacological inhibition of Hsp90 enhances the efficacy of
both azoles and echinocandins against A. fumigatus biofilms
(Figure 9). The synergy between Hsp90 inhibitors and echino-
candins is more pronounced than that with azoles, consistent with
findings in the planktonic cellular state [34]. Thus, targeting
Hsp90 may provide a much-needed strategy to enhance the
efficacy of antifungal drugs against biofilms formed by diverse
fungal pathogens.
Our results provide a new facet to the broader therapeutic
paradigm of Hsp90 inhibitors in the treatment of infectious disease
caused by fungi and other pathogenic eukaryotes. In addition to
the profound effects on biofilm drug resistance and dispersal,
compromising Hsp90 function enhances the efficacy of azoles and
echinocandins against disseminated disease caused by the leading
fungal pathogens of humans in invertebrate and mammalian
models of infection [34,38]. Beyond enhancing antifungal activity,
Hsp90 also provides an attractive antifungal target on its own
given that depletion of fungal Hsp90 results in complete clearance
of a kidney fungal burden in a mouse model of disseminated
candidiasis [41]. Hsp90 inhibitors also exhibit potent activity
against malaria and Trypanosoma infections, thus extending their
spectrum of activity to the protozoan parasites Plasmodium
falciparum and Trypanosoma evansi [35,36]. The development of
Hsp90 as a therapeutic target for infectious disease may benefit
from the plethora of structurally diverse Hsp90 inhibitors that
have been developed, many of which are in advanced phase
clinical trials for cancer treatment, with substantial promise due to
the depletion of a myriad of oncoproteins upon inhibition of
Hsp90 [56]. Given the importance of Hsp90 in chaperoning key
regulators of cellular signalling in all eukaryotes, the challenge of
advancing Hsp90 as a target for infectious disease lies in avoiding
host toxicity issues. Indeed, although well tolerated in the
mammalian host individually or in combination therapies [56],
Hsp90 inhibitors have toxicity in the context of an acute
disseminated fungal infection [34]. This toxicity may be due to
Hsp90’s role in regulating host immune and stress responses
during infection. Toxicity was not observed in our studies of
biofilm infections in the mammalian model, perhaps owing to both
the localized infection and drug delivery, suggesting that this
therapeutic strategy could rapidly translate from the laboratory
bench to the patients’ bedside. In the broader context, the
challenge for further development of Hsp90 as a therapeutic target
for infectious disease lies in developing pathogen-selective
inhibitors or drugs that target pathogen-specific components of
the Hsp90 circuitry governing drug resistance and virulence.
Materials and Methods
Ethics statement
All procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Wisconsin
according to the guidelines of the Animal Welfare Act, The
Institute of Laboratory Animal Resources Guide for the Care and
Use of Laboratory Animals, and Public Health Service Policy.
Strains and culture conditions
Archives of C. albicans strains were maintained at280uC in 25%
glycerol. Strains were routinely maintained and grown in YPD
liquid medium (1% yeast extract, 2% bactopeptone, 2% glucose)
at 30uC. Strains used in this study are listed in Table S1. Strain
construction is described in the Supplemental Material.
Biofilm growth conditions
Multiple in vitro assays were used to assess C. albicans biofilm
growth and antifungal drug susceptibility. In the first model,
biofilms were developed in 96-well polystyrene plates, as
previously described [28,43]. Briefly, strains were grown overnight
in YPD at 37uC. Subsequently, cultures were resuspended in
RPMI medium buffered with HEPES or MOPS, in the presence
or absence of doxycycline (631311, BD Biosciences) to a final
Table 2. Inhibition of Hsp90 has synergistic activity with echinocandins against wild-type A. fumigatus biofilms.
Antifungal concentration range (mg/mL) GdA concentration range (mg/mL) FIC indexa
Micafungin, 64–512 25–100 0.375
Caspofungin, 128–512 12.5–100 0.375
aFIC index (MIC50 of drug A in combination)/(MIC50 of drug A alone) + (MIC50 of drug B in combination)/(MIC50 of drug B alone). A FIC of,0.5 is indicative of synergism.
doi:10.1371/journal.ppat.1002257.t002
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concentration of 106 cells/mL. An aliquot of 100 ml was added to
each well of a 96-well flat-bottom plate, followed by incubation at
37uC. After 24 hours, the wells were gently washed twice with
phosphate-buffered saline (PBS) to remove non-adherent cells, and
fresh medium was added with or without a gradient of
geldanamycin (ant-gl-5, Cedarlane). After 24 hours, non-adherent
cells were washed away with PBS and biofilm cell metabolic
activity was measured using the XTT reduction assay as
previously described [28,43]. Briefly, 90 ml of XTT (X4251,
Sigma) at 1 mg/mL and 10 ml phenazine methosulfate (P9625,
Sigma) at 320 mg/mL were added to each well, followed by
incubation at 37uC for 2 hours. Absorbance of the supernatant
transferred to a fresh plate was measured at 490 nm using an
automated plate reader, and experiments were carried out in a
minimum of 5 replicates for each strain.
In the second model, biofilms were developed on silicon
elastomer (SE) surfaces as has been described previously [57]. C.
albicans wild-type cells were grown overnight in YPD medium at
30uC and diluted to an optical density at 600 nm of 0.5 in RPMI
medium. The suspension was added to a sterile 12-well plate
containing bovine serum (B-9433, Sigma)-treated SE (Cardiovas-
cular Instrument silicon sheets; PR72034-06N) and incubated at
37uC for 90 min at 150 rpm agitation for initial adhesion. The SE
were washed with PBS, transferred to fresh plates containing
either fresh RPMI medium in the absence of drug, or RPMI with
10 mg/mL geldanamycin or 20 mg/mL doxycycline. Plates were
incubated at 37uC for 48 hours at 150 rpm agitation to allow
biofilm formation, followed by visualization by microscopy or by
monitoring biofilm growth by XTT reduction or dry weight, as
previously described [31,43].
C. albicans biofilm dispersion
For obtaining cells dispersed from biofilms, C. albicans biofilms
were cultured in a simple flow biofilm model, as described
previously [47,48]. Briefly, this model involves a controlled flow of
fresh medium via Tygon tubing (Cole-Parmer, Vernon Hills, IL)
into a 15 mL polypropylene conical tube (BD, Franklin, NJ)
holding a SE strip. Medium flow is controlled at 1 mL/minute, by
connecting the tubing to a peristaltic pump (Masterflex L/S Easy-
Load II, Cole-Parmer). The whole apparatus is placed inside an
incubator to facilitate biofilm development at 37uC. SE strips
(169 cm, Cardiovascular instrument Corp, Wakefield, MA), were
sterilized by autoclaving and pre-treated for 24 hours with bovine
serum. C. albicans was grown overnight at 30uC, washed, and
diluted to an optical density at 600 nm of 0.5 in Yeast Nitrogen
base (YNB) medium (BD Biosciences, San Jose, CA) with 50 mM
glucose. The SE strips were incubated with the diluted C. albicans
suspension at 37uC for 90 min at 100 rpm agitation for the initial
adhesion of cells. Next, the strip was inserted into the conical tube
and the peristaltic pump was turned on. At various time points
during biofilm development, cells released from the biofilm in the
flow-through were collected from the bottom of the conical tube.
The dispersed cells were enumerated by a hemocytometer to
obtain cell counts and there were no differences observed in the
degree of clumping or morphological state of the dispersed cells,
which were in the yeast form. Viability of the dispersed cells was
assessed by plating and by colony counts on YPD agar.
C. albicans in vitro biofilm drug susceptibility
Drug susceptibility assays were performed on biofilms formed in
wells of 96-well plates. Fresh medium (RPMI/HEPES) and drugs
were added to wells containing biofilms grown for 24 hours.
Dilutions of fluconazole (Sequoia Research Products) were from
1000 mg/ml down to 0 with the following concentration steps in
mg/ml: 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625,
1.953125, 0.9765625. FK506 (AG Scientific) gradients were from
75 mg/mL down to 0 with the following concentration steps in mg/
ml: 75, 37.5, 18.75, 9.375, 4.6875, 2.3475, 1.171875. Geldana-
mycin gradients were from 100 mg/mL to 0 with the following
concentration steps in mg/ml: 100, 50, 25, 12.5, 6.25, 3.125,
1.5625. Drug combinations were examined alone or in combina-
tion in a checkerboard format. After incubation at 37uC for
24 hours, biofilms were washed twice with PBS and metabolic
activity was measured using the XTT assay, as described above.
The drug concentration associated with 50% reduction in optical
density compared to the drug-free control wells (MIC50) was
determined. The fractional inhibitory concentration (FIC) was
calculated as follows: [(MIC 50 of drug A in combination)/(MIC 50
of drug A alone)] + [(MIC50 of drug B in combination)/(MIC50 of
drug B alone)]. Values of ,0.5 indicates synergy, those of .0.5
but ,2 indicate no interaction, and those of .2 show antagonism
[28].
C. albicans in vivo biofilm model
In order to evaluate biofilm formation in vivo, a rat central
venous catheter infection model was employed [44]. Specific-
pathogen-free Sprague-Dawley rats weighing ,400 g were used
(Harlan Sprague-Dawley, Indianapolis, IN). A heparinized
(100 U/mL) polyethylene catheter was surgically inserted into
the jugular vein and advanced 2 cm to a site above the right
atrium. After the catheter was secured to the vein, the proximal
end was tunneled subcutaneously to the midscapular space and
externalized through the skin. The catheters were implanted
24 hours prior to inoculation with C. albicans to allow a
conditioning period for deposition of host protein on the catheter
surface. Infection was performed by intraluminal instillation of
500 ml of C. albicans (106 cells/mL). After 6 hours, the catheters
were flushed and maintained with heparinized 0.85% NaCl for
24 hours to allow for biofilm formation. While one end of the
catheter is open to the venous blood, most of the fluid contents
remain within the catheter unless pushed into the bloodstream
with additional fluid from the external end. For drug treatment
studies, fluconazole (250 mg/mL), 17-AAG (A-6880, LC Labora-
tories, 100 mg/mL), or saline was instilled and allowed to dwell in
the catheter for an additional 24 hours [28]. For doxycycline
studies, doxycycline (20 mg/mL) was delivered during both the
biofilm formation and the drug treatment phases. At the end of the
observation period, the animals were sacrificed and the catheters
were removed. In order to quantify fungal biofilm formation in the
catheter, the contents were drained to remove blood and non-
adherent organisms. The distal 2 cm of catheter was cut from the
entire catheter length and the segment was placed in 1 mL of
0.85% NaCl. Following sonication for 10 minutes (FS 14 water
bath sonicator and 40-kHz transducer [Fisher Scientific]) and
vigorous vortexing for 30 seconds, serial dilutions of the catheter
fluid were plated on Sabouraud Dextrose Agar (SDA) for viable
fungal colony counts. Results are expressed as the mean colony
forming unit (CFU) per milliliter.
A. fumigatus in vitro biofilm drug susceptibility
Aspergillus fumigatus Af293 was maintained on SDA slopes at 4uC.
For conidial preparation Af293 was propagated on SAB agar for
72 hours and conidia harvested in PBS containing 0.025% (v/v)
Tween 20 and quantified as previously described [58]. Commer-
cially available voriconazole (Pfizer Pharmaceuticals, NY, USA),
micafungin (Astellas Pharma Inc, Ibaraki, Japan) and caspofungin
(Merck Sharp Dohme Ltd, NJ, USA) were used throughout this
study. Each antifungal drug was prepared at stock concentrations
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of 10 mg/mL in sterile water and used within 24 hours of
reconstitution.
Af293 conidial inoculum (16105 conidia/mL) was dispensed
into flat bottomed 96-well microtitre plates and incubated for 8 or
24 hours at 37uC as previously described [58]. Biofilms were
gently washed twice with PBS and each antifungal agent and
geldanamycin were diluted to working concentrations in RPMI,
which were tested either alone or in combination in a
checkerboard format. Antifungal agent dilutions were from
512 mg/ml down to 0 with the following concentration steps in
mg/ml: 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5. Geldanamycin
dilutions were from 100 mg/ml down to 0 with the following
concentration steps in mg/ml: 100, 25, 12.5, 6.25, 3.125, 1.5625.
The biofilms were then treated and processed as described for C.
albicans.
Confocal microscopy
Biofilms were stained with 25 mg/mL concanavalin A–Alexa
Fluor 594 conjugate (C-11253; Molecular Probes, Eugene, OR)
for 1 hour in the dark at 37uC. Confocal scanning laser
microscopy (CSLM) was performed with a ZeissLSM 510 upright
confocal microscope using a Zeiss Achroplan 40X, 0.8-W
objective. Stained biofilms were observed using a HeNe1 laser
with an excitation wavelength of 543 nm. The Zeiss LSM Image
Browser v4.2 software was used to assemble images into side and
depth views. Artificially coloured depth view images represent cell
depth using a colour gradient, where cells closest to the SE are
represented in blue and the cells farthest away are represented in
red.
Scanning electron microscopy
Biofilms formed in vitro were placed overnight in a fixative (4%
formaldehyde v/v, 1% glutaraldehyde v/v in PBS), rinsed in
0.1 M phosphate buffer and air dried in desiccators. Notably,
harsh dehydration steps were not performed to minimize the
damage to the original biofilm structure. The samples were coated
with gold/palladium (40%/60%) and observed under a scanning
electron microscope (Leo 435 VP) in high vacuum mode at 15 kV.
The images were assembled using Photoshop software (Adobe,
Mountain View, CA.).
Catheter segments were processed for scanning electron
microscopy as previously described [44]. Following overnight
fixation (4% formaldehyde, 1% glutaraldehyde in PBS), catheter
segments were washed with PBS and treated with osmium
tetroxide (1% in PBS) for 30 minutes. Drying was accomplished
using a series of alcohol washes followed by critical point drying.
Catheter segments were mounted and gold coated. Images were
obtained with a scanning electron microscope (JEOL JSM-6100)
in the high-vacuum mode at 10 kV. The images were assembled
using Adobe Photoshop 7.0.1.
Immune blot analysis
For the protein stability assay, planktonic cultures were grown
in RPMI buffered with MOPS and treated as described previously
[39]. For biofilm cultures, C. albicans was grown overnight in YPD
medium at 30uC and diluted to an optical density at 600 nm of 0.5
in RPMI medium. The suspension was added to a bovine serum
(16190; Gibco)-treated sterile 6-well plate and incubated at 37uC
for 90 minutes for initial adhesion. The plates were washed with
PBS, and fresh RPMI medium was added with or without 20 mg/
mL doxycycline. Plates were incubated at 37uC for 48 hours.
Cells were harvested by centrifugation and were washed with
sterile water. Cell pellets were resuspended in lysis buffer
containing 50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 1 mM PMSF, and protease inhibitor
cocktail (complete, EDTA-free tablet, Roche Diagnostics). Cells
suspended in lysis buffer were mechanically disrupted by adding
acid-washed glass beads and bead beating for 3 minutes. Protein
concentrations were determined by Bradford analysis. Protein
samples were mixed with one-sixth volume of 6X sample buffer
containing 0.35 M Tris-HCl, 10% (w/v) SDS, 36% glycerol, 5%
b-mercaptoethanol, and 0.012% bromophenol blue for SDS-
PAGE. Samples were boiled for 5 minutes and then separated by
SDS-PAGE using an 8% acrylamide gel. Proteins were electro-
transferred to PVDF membranes (Bio-Rad Laboratories, Inc.) and
blocked with 5% skimmed milk in phosphate buffered saline (PBS)
with 0.1% tween. Blots were hybridized with antibodies against
CaHsp90 (1:10000), generously provided by Brian Larsen [59],
FLAG (1:10000, Sigma Aldrich Co.), His6 (1:10, P5A11,
generously provided by Elizabeth Wayner), phospho-p44/42
MAPK (Thr202/Tyr204) (1:2000, Cell Signaling), or against
alpha-tubulin (1:1000; AbD Serotec, MCA78G).
Biofilm matrix collection and matrix b-1,3 glucan
measurements
Matrix b-1,3 glucan content was measured using a limulus
lysate based assay, as previously described [28,60]. Matrix was
collected from C. albicans biofilms growing in the wells of 6-well
polystyrene plates with or without 20 mg/mL doxycycline for
48 hours. The method for culturing biofilms was as described
above for the immune blot analysis with the exception that all
reagents were glucan-free. Biofilms were dislodged using a sterile
spatula, washed with PBS, sonicated for 10 minutes, and
centrifuged 3 times at 4500 x g for 20 minutes to separate cells
from soluble matrix material [28,61]. Samples were stored at -
20uC and glucan concentrations were determined using the
Glucatell (1,3)-Beta-D-Glucan Detection Reagent Kit (Associates
of Cape Cod, MA) as per the manufacturer’s directions.
Accession numbers for genes and proteins mentioned in
text (NCBI Entrez Gene ID number)
C. albicans: PKC1 (3635298); HSP90 (3637507); CNA1 (3639406);
CNB1 (3636463); MKC1 (3639710); ERG11 (3641571); FKS1
(3637073); SSB1 (3642206); GCA1 (3635124); ZAP1 (3641162).
Supporting Information
Figure S1 The impact of Hsp90 depletion on C. albicans
biofilm formation and maturation in multiple models.
(A) A wild-type strain of C. albicans and the tetO-HSP90/hsp90D
strain were grown on silicon elastomer squares in RPMI at 37uC
for 24 hours with or without 20 mg/mL doxycycline (DOX).
Metabolic activity was measured as in Figure 1A. Treatment of
wild-type biofilms with DOX did not alter biofilm growth, while
Hsp90 depletion caused a moderate but significant reduction in
biofilm growth (P,0.01, ANOVA, Bonferroni’s Multiple Com-
parison Test). (B) Biofilms were grown as in part A, but growth
was measured by dry weight. Treatment of wild-type biofilms with
DOX did not alter biofilm growth, while Hsp90 depletion caused
a moderate but significant reduction in biofilm growth (P,0.05).
(C) The tetO-HSP90/hsp90D strain was grown with or without
20 mg/mL DOX in the overnight culture as well as during biofilm
formation on plastic under static conditions. Metabolic activity was
measured as in Figure 1A. Depletion of Hsp90 does not block
biofilm formation. (D) Biofilms were cultured on plastic under
shaking conditions with or without 20 mg/mL DOX. Treatment
of wild-type biofilms with DOX did not alter biofilm growth. The
tetO-HSP90/hsp90D strain showed impaired biofilm development
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(P,0.001), which was exacerbated in the presence of 20 mg/mL
DOX. This is consistent with impaired HSP90 induction in
response to many conditions when driven by the non-native tetO
promoter and the further transcriptional repression of HSP90 with
DOX [4].
(TIF)
Figure S2 Treating C. albicans with doxycycline does
not impair biofilm dispersal. (A) A wild-type strain of C.
albicans lacking the tetO promoter was cultured in the presence or
absence of 20 mg/mL doxycycline (DOX). The number of
dispersed cells released from biofilms was monitored over a
24 hour period. (B) The viability of dispersed cells from a wild-
type C. albicans strain was determined by plating on YPD agar.
DOX has no effect on biofilm dispersal or viability in a wild-type
strain.
(TIF)
Figure S3 Pharmacological inhibition of Hsp90 enhanc-
es the efficacy of echinocandins and azoles against A.
fumigatus biofilms. A. fumigatus was grown in 96-well
microtiter plates in RPMI at 37uC. (A) After 24 hours cells were
washed with PBS to remove non-adherent cells and fresh media
was added with varying concentrations of the echinocandin
micafungin (MF) in combination with the Hsp90 inhibitor
geldanamycin (GdA) in a checkerboard format, and incubated
with the biofilm for 24 hours. Metabolic activity was measured as
in Figure 1A. The FIC index was calculated as indicated in
Table 2. Bright green represents growth above the MIC50, dull
green represents growth at the MIC50, and black represents
growth below the MIC50. (B) After 8 hours cells were washed with
PBS to remove non-adherent cells and fresh media was added with
varying concentrations of the azole voriconazole (VL) in
combination with GdA in a checkerboard format, and incubated
with the biofilm for 24 hours. Metabolic activity was measured as
in Figure 1A and data analyzed as in Figure S3A.
(TIF)
Table S1 C. albicans strains used in this study.
(DOC)
Text S1 Supporting materials and methods.
(DOC)
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